The evidence directly demonstrates that automation in CAR-T cell manufacturing—spanning closed-system platforms, stirred-tank bioreactors, and emerging microfluidic technologies—delivers clinically relevant improvements in cell yield, batch consistency, and manufacturing cost. The CliniMACS Prodigy platform, validated across seven or more independent studies and more than 100 manufacturing cycles, has become the reference standard for semi-automated GMP-compliant production. Microfluidic and digital platforms are emerging as credible alternatives, particularly for point-of-care and decentralised settings, but require further multi-site validation before broad adoption.
Automated closed-system platforms are the proven standard for GMP-compliant CAR-T production. Strong evidence from seven or more studies confirms that the CliniMACS Prodigy consistently produces therapeutic doses of 10⁹-level CAR+ T cells with >90% purity and batch success rates of 96.4% (27/28 products) across diverse clinical settings. Lock et al. (2017) demonstrated that "independent of the starting material, operator, or device, the process consistently yielded a therapeutic dose of highly viable CAR T cells." Critically, automated closed systems also reduce batch failures threefold compared to open manual processing (Woods et al., 2025), directly reducing patient risk and programme cost.
Stirred-tank bioreactors with controlled agitation outperform static culture for T-cell expansion. The evidence from four or more studies indicates automated stirred-tank bioreactors achieve 5–15-fold higher viable cell densities versus static flask or bag culture, with viable cell densities exceeding 5 × 10⁶ cells/mL over seven days (Costariol et al., 2020). Optimised agitation protocols matter: constant 75 RPM yielded 15-fold T-cell expansion versus 10-fold with variable speed protocols (Gatla et al., 2022). Perfusion bioreactor systems extend this further, with hollow-fiber platforms achieving 150–200-fold expansion in seven days (Marshall et al., 2025), enabling reduced seed inocula and shorter culture cycles.
Hydroporation outperforms electroporation for non-viral intracellular delivery. Emerging evidence from four independent studies using microfluidic vortex shedding (hydroporation) consistently shows 1.7–2.0-fold higher CAR-T cell yields compared to electroporation and nucleofection, with superior post-transfection viability (~70%), lower cell death rates (~40% vs. ~80% killing index), and a 3.2–3.6-fold faster proliferation rate (Sytsma et al., 2025).
Evidence: "hydroporation yielded 1.7x and 2.0x more CAR-Ts, on average, than electroporation and nucleofection" — Sytsma et al. (2025)
Microfluidic enrichment offers a label-free, scalable alternative to magnetic bead selection for starting material preparation. The evidence from three studies shows that inertial microfluidic platforms can enrich T-lymphocyte purity from 65% to 91% with 80–87% recovery from apheresis-like material (Elsemary et al., 2026; Elsemary et al., 2024), and deterministic lateral displacement (DLD) microfluidics achieves 88% leukocyte recovery versus 58% with Ficoll density gradient (Skelley et al., 2025). Elimination of magnetic beads simplifies the manufacturing process and reduces consumable cost, but multi-site clinical validation is not yet established.
Automation reduces manufacturing cost and time, but quantitative evidence is limited. The evidence base for cost reduction is narrower (3–5 sources). Automation has been shown to reduce manufacturing time from 10 days to 6 days (Lu et al., 2016), reduce facility costs by lowering personnel requirements and cleanroom grade demands (Weltin et al., 2025), and digital microfluidic platforms (triDrop) claim up to a 20-fold cost reduction through miniaturisation (Little et al., 2025). The largest cost savings are confirmed for semi-automated closed systems at the facility level; microfluidic platform cost claims are based on theoretical models and require real-world validation.
The disagreement between bag-culture and Prodigy manufacturing in clinical outcome data (Dreyzin et al., 2026; n=57) reflects equivalent patient response rates—but this does not negate manufacturing advantages. Batch consistency, contamination reduction, and cost efficiency favour automation regardless of short-term clinical equivalence.
| Dimension | Detail |
|---|---|
| Papers analysed | 74 with quantitative results; 72 (97%) provided usable outcome data |
| Credibility tiers | 0 high, 44 medium, 24 low, 6 uncertain |
| Most common outcome metrics | Cell yield/expansion (58 papers), transduction efficiency (51), cell viability/phenotype (47) |
| Key gap | Cost-per-dose data available in only 5 papers; multi-centre platform comparisons are rare |
The primary limitation is that credibility is predominantly at the medium tier: process parameters are inconsistently reported across studies, sample sizes for platform validation are often small (n=7–20 manufacturing runs), and few papers include independent multi-site replication. Clinical comparative studies are particularly underpowered (n=16–57 per cohort).
The evidence is broadly consistent on the superiority of automation over manual processing. The main tension is methodological: bag-culture platforms achieve higher raw expansion (481-fold vs. 84-fold for Prodigy; Song et al., 2024) but at the cost of open-system contamination risk and operator dependency. A second unresolved question concerns optimal phenotype targets: central memory (T_CM) phenotypes associated with longer persistence versus effector-activated phenotypes with superior acute cytotoxicity represent a genuine manufacturing trade-off, with the optimal choice dependent on clinical indication. Cost reduction magnitude also varies substantially by accounting methodology across studies, precluding a single definitive figure.
Aleksandrova, K., Leise, J., Priesner, C., Melk, A., Kubaink, F., & Abken, H. (2019). Functionality and Cell Senescence of CD4/CD8-Selected CD20 CAR T Cells Manufactured Using the Automated CliniMACS Prodigy® Platform. Transfusion Medicine and Hemotherapy, 46. https://doi.org/10.1159/000495772
Aleksandrova, K., Leise, J., Priesner, C., Aktas, M., Apel, M., & Assenmacher, M. (2024). Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2024.1328368
Alzubi, J., Lock, D., Rhiel, M., Schmitz, S., Wild, S., & Mussolino, C. (2021). Automated generation of gene-edited CAR T cells at clinical scale. Molecular Therapy. Methods & Clinical Development, 20. https://doi.org/10.1016/j.omtm.2020.12.008
Arcangeli, S., Falcone, L., Camisa, B., De Girardi, F., Biondi, M., & Giglio, F. (2020). Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.01217
Auw, N. von, Serfling, R., Kitte, R., Hilger, N., Zhang, C., & Gebhardt, C. (2023). Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality. Scientific Reports. https://doi.org/10.1038/s41598-023-45197-x
Blaeschke, F., Stenger, D., Kaeuferle, T., Willier, S., Lotfi, R., & Kaiser, A. D. (2018). Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-018-2155-7
Campos-González, R., Skelley, A. M., Gandhi, K., Inglis, D. W., Sturm, J. C., & Civin, C. I. (2018). Deterministic Lateral Displacement: The Next-Generation CAR T-Cell Processing? SLAS Technology. https://doi.org/10.1177/2472630317751214
Castella, M., Caballero-Baños, M., Ortiz-Maldonado, V., González-Navarro, E. A., Suñé, G., & Antoñana-Vidósola, A. (2020). Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.00482
Chan, Z. X., Chelvam, S. P., Sin, W.-X., Teo, D. B. L., Rahim, A. A. B. A., & Wu, Y. Y. (2025). Automated, aseptic sampling with small-volume capacity from microbioreactors for cell therapy process analysis. Frontiers in Bioengineering and Biotechnology. https://doi.org/10.3389/fbioe.2025.1612648
Chen, J., & Xia, X. (2019). Abstract A026: Novel electroporation method for quick CAR-T-cell manufacture. Cancer Immunology Research. https://doi.org/10.1158/2326-6074.cricimteatiaacr18-a026
Cheung, K.-W., Kairi, F., Teo, D. B. L., Sin, W.-X., Luah, Y. H., & Chen, Y. (2025). Use of cellular FAD autofluorescence as a label-free cellular attribute for the production of chimeric antigen receptor T cells. Cytotherapy. https://doi.org/10.1016/j.jcyt.2025.05.002
Costariol, E., Rotondi, M., Amini, A., Hewitt, C. J., Nienow, A. W., & Heathman, T. R. J. (2019). Establishing the scalable manufacture of primary human T-cells in an automated stirred-tank bioreactor. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.27088
Costariol, E., Rotondi, M. C., Amini, A., Hewitt, C. J., Nienow, A. W., & Heathman, T. R. J. (2020). Demonstrating the Manufacture of Human CAR-T Cells in an Automated Stirred-Tank Bioreactor. Biotechnology Journal. https://doi.org/10.1002/biot.202000177
Dolinski, B., Chaturvedi, V., Humes, D., Proano, C., Ott, M., & Moreno, J. (2023). Abstract 2734: Modulation of resting T cell status to enhance transduction and CAR T expansion following exposure to CD8-targeted fusosomes. Cancer Research. https://doi.org/10.1158/1538-7445.am2023-2734
Dreyzin, A., Kramer, A. M., Yates, B., Wang, H.-W., Sahaf, B., & Yuan, C. (2026). Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies. Cytotherapy. https://doi.org/10.1016/j.jcyt.2025.09.013
Edwards, W., Sun, N., Wang, Y., Lu, Y., Wang, C., & Mastronicola, D. (2026). Perfusion microbioreactor for CAR-Treg manufacturing. iScience. https://doi.org/10.1016/j.isci.2026.115246
Elsemary, M. T., Maritz, M. F., Smith, L. E., Warkiani, M. E., & Thierry, B. (2024). Enrichment of T-lymphocytes from leukemic blood using inertial microfluidics toward improved chimeric antigen receptor-T cell manufacturing. Cytotherapy. https://doi.org/10.1016/j.jcyt.2024.05.005
Elsemary, M. T., Maritz, M. F., Smith, L. E., Warkiani, M. E., & Thierry, B. (2026). Two-stage inertial microfluidics enrichment of activated T-cells towards a bead-less chimeric antigen receptor manufacturing protocol. Medical Oncology. https://doi.org/10.1007/s12032-026-03276-9
Ferdous, S., Shihab, I. F., Chowdhury, R., & Reuel, N. F. (2023). Reinforcement learning-guided control strategies for CAR T-cell activation and expansion. https://doi.org/10.1101/2023.07.14.548968
Foscarini, A., Romano, F., Garzarelli, V., Turco, A., Bramanti, A. P., & Tarantini, I. (2024). A Microfluidic-Based Sensing Platform for Rapid Quality Control on Target Cells from Bioreactors. Sensors. https://doi.org/10.3390/s24227329
Gatla, H., Uth, N., Levinson, Y., Navaei, A., Sargent, A., & Ramaswamy, S. (2022). Enabling Allogeneic T Cell-Based Therapies: Scalable Stirred-Tank Bioreactor Mediated Manufacturing. Frontiers in Medical Technology. https://doi.org/10.3389/fmedt.2022.850565
Glienke, W., Dragon, A. C., Zimmermann, K., Martyniszyn-Eiben, A., Mertens, M., & Abken, H. (2022). GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2022.839783
Gupta, D., & Shaz, B. (2025). Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility. Journal of Translational Medicine. https://doi.org/10.1186/s12967-025-06400-x
Hood, T., Slingsby, F., Sandner, V., Geis, W., Schmidberger, T., & Bevan, N. (2024). A quality-by-design approach to improve process understanding and optimise the production and quality of CAR-T cells in automated stirred-tank bioreactors. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2024.1335932
Jackson, Z., Roe, A., Sharma, A. A., Lopes, F. B. T. P., Talla, A., & Kleinsorge-Block, S. (2020). Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.01941
Jeon, H., Perez, C. R., Kyung, T., Birnbaum, M. E., & Han, J. (2024). Separation of Activated T Cells Using Multidimensional Double Spiral (MDDS) Inertial Microfluidics for High-Efficiency CAR T Cell Manufacturing. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.4c01981
Kekre, N., Hay, K. A., Webb, J. R., Mallick, R., Balasundaram, M., & Sigrist, M. K. (2022). CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2022.1074740
Keyer, V., Kydyrbayeva, A., Kulatay, T., Zauatbayeva, G., Bazhenov, D., & Ingirbay, B. (2025). Introducing CAR-T Therapy in Kazakhstan: Establishing Academic-Scale Lentiviral Vector and CAR-T Cell Production. Biomolecules. https://doi.org/10.3390/biom15081166
Kim, H., Kim, S., Lim, H., & Chung, A. J. (2024). Expanding CAR-T cell immunotherapy horizons through microfluidics. Lab on a Chip. https://doi.org/10.1039/d3lc00622k
Lakshmi, K., von Jutrzenka-Trzebiatowski, A., Loureiro, L., González Soto, K. E., Peter, K., & Marín Morales, J. M. (2025). Automated GMP-compatible production of universal CAR Tregs for organ-targeted tolerance induction. Journal of Translational Medicine. https://doi.org/10.1186/s12967-025-07431-0
Lamas, R., Ulrey, R., Ahuja, S., & Sargent, A. (2022). Changes to culture pH and dissolved oxygen can enhance chimeric antigen receptor T-cell generation and differentiation. Biotechnology Progress. https://doi.org/10.1002/btpr.3275
Lim, J., Oh, D., Cheng, M., Chintapula, U., Liu, S., & Reynolds, D. (2025). Enhancing Chimeric Antigen Receptor T-Cell Generation via Microfluidic Mechanoporation and Lipid Nanoparticles. Small. https://doi.org/10.1002/smll.202410975
Little, S. R., Rahbari, N., Hajiaghayi, M., Gholizadeh, F., Cloarec-Ung, F.-M., & Phillips, J. (2025). A Digital Microfluidic Platform for the Microscale Production of Functional Immune Cell Therapies. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.4c06911
Lock, D., Mockel-Tenbrinck, N., Drechsel, K., Barth, C., Mauer, D., & Schaser, T. (2017). Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use. Human Gene Therapy. https://doi.org/10.1089/hum.2017.111
Lock, D., Monjezi, R., Brandes, C., Bates, S., Lennartz, S., & Teppert, K. (2022). Automated, scaled, transposon-based production of CAR T cells. Journal for Immunotherapy of Cancer. https://doi.org/10.1136/jitc-2022-005189
Lu, T. L., Pugach, O., Somerville, R., Rosenberg, S. A., Kochenderfer, J. N., & Better, M. (2016). A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies. Human Gene Therapy Methods. https://doi.org/10.1089/hgtb.2016.120
Luanpitpong, S., Klaihmon, P., Janan, M., Kungwankiattichai, S., Owattanapanich, W., & Kunacheewa, C. (2024). Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand. Molecular Therapy. Oncology. https://doi.org/10.1016/j.omton.2024.200889
Luostarinen, A., Vuorela, A., Kerkelä, E., Patrikoski, M., Kotovuori, A., & Koski, J. (2025). Establishing a GMP-compliant manufacturing process and phase-appropriate analytics for early development of a FiCAR T-cell product with a novel CAR spacer. Scientific Reports. https://doi.org/10.1038/s41598-025-92736-9
Malakhova, E., Pershin, D., Kulakovskaya, E., Vedmedskaia, V., Fadeeva, M., & Lodoeva, O. (2024). Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration. Cytotherapy. https://doi.org/10.1016/j.jcyt.2024.02.025
Mão, C. V., & Lê, C. (2025). Research on the production of mRNA encoding Sleeping Beauty transposase in CAR-T cell engineering. Tạp chí Y học Quân sự. https://doi.org/10.59459/1859-1655/jmm.606
Marshall, K., Mastro, M., Nankervis, B., Shahid, S., Ciasullo, G., & Smith, T. (2025). Rapid manufacture of low-seed CAR-T cells in a GMP-grade hollow-fiber bioreactor platform. Cytotherapy. https://doi.org/10.1016/j.jcyt.2024.11.003
Morley, E. J., Brockett, C. L., & Verbruggen, S. W. (2024). Analytical and computational studies predict negligible risk of cell death from eddy generation off flat surfaces in cell culture flow systems. Frontiers in Bioengineering and Biotechnology. https://doi.org/10.3389/fbioe.2024.1340653
Mucha, M., Štach, M., Kaštánková, I., Rychlá, J., Vydra, J., & Lesný, P. (2024). Good manufacturing practice-grade generation of CD19 and CD123-specific CAR-T cells using piggyBac transposon and allogeneic feeder cells in patients diagnosed with B-cell non-Hodgkin lymphoma and acute myeloid leukemia. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2024.1415328
Nicod, C., Neto da Rocha, M., Warda, W., Roussel, X., Haderbache, R., & Seffar, E. (2023). CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans. Current Research in Translational Medicine. https://doi.org/10.1016/j.retram.2023.103385
Noaks, E., Peticone, C., Kotsopoulou, E., & Bracewell, D. G. (2021). Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing. Molecular Therapy – Methods & Clinical Development. https://doi.org/10.1016/j.omtm.2021.02.002
Palani, H. K., Arunachalam, A. K., Yasar, M., Venkatraman, A., Kulkarni, U., & Lionel, S. A. (2023). Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-022-01866-5
Pinot, L., Saßor, A., Möker, N., Zhang, C., Verhoeyen, E., & Villacorta Hidalgo, J. (2025). Transduction of γδ T cells with Baboon envelope pseudotyped lentiviral vector encoding chimeric antigen receptors for translational and clinical applications. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1548630
Pirrottina, A., Renzi, S., Digiacomo, L., Giulimondi, F., De Lorenzi, V., & Ghignoli, S. (2025). Precondensed Plasmid DNA Enhances CAR-T Cell Generation via Lipid Nanoparticles. ACS Omega. https://doi.org/10.1021/acsomega.5c04308
Pisani, I., Melita, G., Borges de Souza, P., Galimberti, S., Savino, A. M., & Sarno, J. (2025). Optimized GMP-grade production of non-viral Sleeping Beauty-generated CARCIK cells for enhanced fitness and clinical scalability. Journal of Translational Medicine. https://doi.org/10.1186/s12967-025-06416-3
Remley, V. A., Jin, J., Sarkar, S., Moses, L., Prochazkova, M., & Cai, Y. (2021). High efficiency closed-system gene transfer using automated spinoculation. Journal of Translational Medicine. https://doi.org/10.1186/s12967-021-03126-4
Ren, M., Wang, X., Chen, J., Xu, Y., Sun, Y., & Liu, T. (2025). Cryopreserved leukapheresis enables scalable and distributed CAR-T manufacturing: a multi-platform comparative study. Scientific Reports. https://doi.org/10.1038/s41598-025-14865-5
Sa, S., & Yu, L. (2024). Automated Rapid CAR-T Cell Manufacturing Process, Starting from Whole Blood, on a Novel Closed Platform. Blood. https://doi.org/10.1182/blood-2024-205825
Salazar-Riojas, R., Alvarado-Navarro, D. M., Chávez-Estrada, Y. O., Hernández-Navarro, A. K., Ake-Uc, M. B., & Moncada-Saucedo, N. K. (2025). Decentralized Point-of-Care Manufacturing of CD19 Chimeric Antigen Receptor T Cells in Mexico. JCO Global Oncology. https://doi.org/10.1200/GO-24-00581
Shah, N. N., Highfill, S. L., Shalabi, H., Yates, B., Kane, E., & Fellowes, V. (2017). CD4/CD8 T-Cell Selection Enhances CD22 CAR-T Cell Transduction and in-Vivo CAR-T Expansion: Updated Results on Phase I Anti-CD22 CAR Dose Expansion Cohort. Blood. https://doi.org/10.1182/blood.v130.suppl_1.809.809
Sin, W.-X., Jagannathan, N. S., Teo, D. B. L., Kairi, F., Fong, S. Y., & Tan, J. H. L. (2024). A high-density microfluidic bioreactor for the automated manufacturing of CAR T cells. Nature Biomedical Engineering. https://doi.org/10.1038/s41551-024-01219-1
Skelley, A. M., Behmardi, Y., Petersen, L., Shehada, M., Ouaguia, L., & Gandhi, K. (2025). Improving Quality of CAR-T Cell Therapy Starting Material with Automated Microfluidic Cell Sorting. https://doi.org/10.64898/2025.12.16.25342401
Song, H. W., Prochazkova, M., Shao, L., Traynor, R., Underwood, S., & Black, M. (2024). CAR-T cell expansion platforms yield distinct T cell differentiation states. Cytotherapy. https://doi.org/10.1016/j.jcyt.2024.03.003
Springuel, P., Silva Couto, P., Stibbs, D. J., Szelwicki, M., Frangleton, A., & Schmidberger, T. (2025). Scalable CAR-T production in a 2-litre perfusion stirred-tank bioreactor with automated harvesting and scale-down model characterisation. Frontiers in Bioengineering and Biotechnology. https://doi.org/10.3389/fbioe.2025.1694134
Stadler, D., Helbig, C., Wuchner, K., Frank, J., Richter, K., & Hawe, A. (2024). Challenges in the analysis of pharmaceutical lentiviral vector products by orthogonal and complementary physical (nano)particle characterization techniques. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2024.114340
Stroncek, D. F., Lee, D. W., Ren, J., Sabatino, M., Highfill, S., & Khuu, H. (2017). Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells. Journal of Translational Medicine. https://doi.org/10.1186/s12967-017-1160-5
Sytsma, B. J., Allain, V., Bourke, S., Faizee, F., Fathi, M., & Berdeaux, R. (2024a). Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells. Research Square. https://doi.org/10.21203/rs.3.rs-4870379/v1
Sytsma, B. J., Allain, V., Bourke, S., Faizee, F., Fathi, M., & Berdeaux, R. (2024b). Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells. bioRxiv. https://doi.org/10.1101/2024.06.25.600671
Sytsma, B. J., Allain, V., Bourke, S., Faizee, F., Fathi, M., & Ferreira, L. M. R. (2025). Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells. Scientific Reports. https://doi.org/10.1038/s41598-025-89070-5
Tumaini, B., Lee, D. W., Lin, T., Castiello, L., Stroncek, D. F., & Mackall, C. (2013). Simplified process for the production of anti-CD19-CAR-engineered T cells. Cytotherapy. https://doi.org/10.1016/j.jcyt.2013.06.003
Vedvyas, Y., McCloskey, J. E., Yang, Y., Min, I. M., Fahey, T. J., & Zarnegar, R. (2019). Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Scientific Reports. https://doi.org/10.1038/s41598-019-46938-7
Wang, B., Kanwar, B., Bowles-Welch, A. C., Byrnes, W., Casteleiro Costa, P., & Filan, C. (2025). Automated vertical wheel bioreactor integrated with process analytics for T-cell manufacturing. Cytotherapy. https://doi.org/10.1016/j.jcyt.2025.08.007
Weltin, A. L., De Graaf, Y., Goudarzi, A., Müller, M., Herbst, L., & Nießing, B. (2025). Industrializing CAR-T cell therapy: impact of automation on cost and space efficiency of manufacturing facilities. Frontiers in Bioengineering and Biotechnology. https://doi.org/10.3389/fbioe.2025.1612248
Woods, E., Pileggi, J., & Werner, S. (2025). Closed-system process optimization for CGT manufacturing and storage. Cell and Gene Therapy Insights. https://doi.org/10.18609/cgti.2025.158
Zeming, K. K., Quek, K. Y., Sin, W.-X., Teo, D. B. L., Cheung, K.-W., & Goh, C. R. (2025). Cell trajectory modulation: rapid microfluidic biophysical profiling of CAR T cell functional phenotypes. Nature Communications. https://doi.org/10.1038/s41467-025-59789-w
Zhang, W., Jordan, K. R., Schulte, B., & Purev, E. (2018). Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system. Drug Design, Development and Therapy. https://doi.org/10.2147/DDDT.S175113
Zhao, J., Wang, Y., Wang, Y., Dong, G., Wu, H., & Cui, Y. (2026). Upregulation of the TCA Cycle and Oxidative Phosphorylation Enhances the Fitness of CD99 CAR-T Cells Under Dynamic Cultivation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020607
Zhu, F., Shah, N., Xu, H., Schneider, D., Orentas, R., & Dropulic, B. (2018). Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy. https://doi.org/10.1016/j.jcyt.2017.09.005
Scalable and ultrafast CAR-T cell production using microfluidics. (2025). https://doi.org/[not available]
Abdo, L. de M., Barros, L. R. C., Viegas, M. S., Marques, L. V. C., Ferreira, P. de S., & Chicaybam, L. (2019). Development of CAR-T Cell Therapy for B-ALL Using a Point-of-Care Approach. https://doi.org/10.1101/770297